Nasus Pharma Ltd, a clinical-stage specialty pharmaceutical company focused on intranasal drug delivery for emergency conditions, has demonstrated faster epinephrine delivery with its lead candidate NS002 compared to traditional EpiPen injections. Despite significant R&D progress and proprietary Powder-Based Inhalation technology, the company remains unprofitable with a net loss of $5.86 million in 2025 and limited cash reserves. Nasus plans a pivotal Phase 3 trial for NS002 by late 2026 but faces substantial regulatory, reimbursement, and competitive risks in the nascent intranasal emergency drug market.